Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5801063 | 0.92 | — | — | |
| SCHEMBL5798108 | 0.84 | SMN1; SMN2 (0.44) | MAPTALDH1A1HTTL3MBTL1POLB | |
| SCHEMBL6322778 | 0.83 | MEN1 (0.43) | MAPTSMN1; SMN2MEN1RAB9AKMT2A | |
| SCHEMBL5777986 | 0.82 | — | — | |
| SCHEMBL5775125 | 0.78 | — | — | |
| SCHEMBL5778672 | 0.77 | — | — | |
| SCHEMBL5777405 | 0.77 | — | — | |
| SCHEMBL5776323 | 0.77 | — | — | |
| SCHEMBL5797601 | 0.77 | SMN1; SMN2 (0.42) | SMN1; SMN2 | |
| SCHEMBL5778601 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1472254-A4 | PURINE AND ISOSTERIC ANTIBACTERIAL COMPOUNDS | GLSYNTHESIS INC (US) | 2006-02-15 | — | — | EP | claimed |
| EP-1472254-A2 | PURINE AND ISOSTERIC ANTIBACTERIAL COMPOUNDS | Glsynthesis Inc. (US) | 2004-11-03 | — | — | EP | claimed |
| US-20040014773-A1 | Purine and isosteric antibacterial compounds | ACURX PHARMACEUTICALS, LLC | 2004-01-22 | — | — | US | claimed |
| WO-2003066586-A2 | PURINE AND ISOSTERIC ANTIBACTERIAL COMPOUNDS | GLSYNTHESIS INC. (US) | 2003-08-14 | — | — | WO | claimed |
| US-6926763-B2 | Purine and isosteric antibacterial compounds | GLSYNTHESIS, INC. (US) | 2005-08-09 | — | — | US | disclosed |
| US-20040014773-A1 | Purine and isosteric antibacterial compounds | ACURX PHARMACEUTICALS, LLC | 2004-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014773-A1 | Purine and isosteric antibacterial compounds | MTAP, AMPD3, MPG | MAPT 2059/4885ALDH1A1 2828/4885HTT 2965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.